menu
    • menu
    [{"orgOrder":0,"company":"GENERAL ELECTRIC","sponsor":"GENERAL ELECTRIC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"68-Ga BAY86-7548","moa":"Amyloid-beta-plaque","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GENERAL ELECTRIC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GENERAL ELECTRIC \/ GENERAL ELECTRIC","highestDevelopmentStatusID":"7","companyTruncated":"GENERAL ELECTRIC \/ GENERAL ELECTRIC"},{"orgOrder":0,"company":"GENERAL ELECTRIC","sponsor":"GENERAL ELECTRIC","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Nephrology","graph2":"Phase IV","graph3":"GENERAL ELECTRIC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GENERAL ELECTRIC \/ GENERAL ELECTRIC","highestDevelopmentStatusID":"11","companyTruncated":"GENERAL ELECTRIC \/ GENERAL ELECTRIC"},{"orgOrder":0,"company":"GENERAL ELECTRIC","sponsor":"GENERAL ELECTRIC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"68-Ga RM2","moa":"GRPr","graph1":"Oncology","graph2":"Phase II","graph3":"GENERAL ELECTRIC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GENERAL ELECTRIC \/ GENERAL ELECTRIC","highestDevelopmentStatusID":"8","companyTruncated":"GENERAL ELECTRIC \/ GENERAL ELECTRIC"},{"orgOrder":0,"company":"GENERAL ELECTRIC","sponsor":"GENERAL ELECTRIC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"68-Ga RM2","moa":"GRPr","graph1":"Oncology","graph2":"Phase II","graph3":"GENERAL ELECTRIC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GENERAL ELECTRIC \/ GENERAL ELECTRIC","highestDevelopmentStatusID":"8","companyTruncated":"GENERAL ELECTRIC \/ GENERAL ELECTRIC"},{"orgOrder":0,"company":"GENERAL ELECTRIC","sponsor":"GENERAL ELECTRIC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Iodixanol","moa":"iodine-containing contrast media","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"GENERAL ELECTRIC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Catheter","sponsorNew":"GENERAL ELECTRIC \/ GENERAL ELECTRIC","highestDevelopmentStatusID":"1","companyTruncated":"GENERAL ELECTRIC \/ GENERAL ELECTRIC"},{"orgOrder":0,"company":"GENERAL ELECTRIC","sponsor":"GENERAL ELECTRIC","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Autologous Platelet Rich Plasma","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"GENERAL ELECTRIC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"GENERAL ELECTRIC \/ GENERAL ELECTRIC","highestDevelopmentStatusID":"8","companyTruncated":"GENERAL ELECTRIC \/ GENERAL ELECTRIC"},{"orgOrder":0,"company":"GENERAL ELECTRIC","sponsor":"GENERAL ELECTRIC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Manganese-Enhanced Mri Contrast Reagent","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"GENERAL ELECTRIC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GENERAL ELECTRIC \/ GENERAL ELECTRIC","highestDevelopmentStatusID":"7","companyTruncated":"GENERAL ELECTRIC \/ GENERAL ELECTRIC"}]

    Find Clinical Drug Pipeline Developments & Deals by GENERAL ELECTRIC

    Menu

    GENERAL ELECTRIC

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GENERAL ELECTRIC

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            GENERAL ELECTRIC

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga RM2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Andrei Iagaru

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

                            Details : 68-Ga RM2 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            May 14, 2019

                            Lead Product(s) : 68-Ga RM2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Andrei Iagaru

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GENERAL ELECTRIC

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            GENERAL ELECTRIC

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga BAY86-7548

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Andrei Iagaru

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

                            Details : 68-Ga BAY86-7548 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            February 06, 2019

                            Lead Product(s) : 68-Ga BAY86-7548

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Andrei Iagaru

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GENERAL ELECTRIC

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            GENERAL ELECTRIC

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga RM2

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Andrei Iagaru

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

                            Details : 68-Ga RM2 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            January 18, 2019

                            Lead Product(s) : 68-Ga RM2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Andrei Iagaru

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GENERAL ELECTRIC

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            GENERAL ELECTRIC

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Platelet Rich Plasma

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Recipient : University of Wisconsin, Madison

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Platelet-Rich Plasma Therapy for Patellar Tendinopathy

                            Details : Autologous Platelet Rich Plasma is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tendinopathy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 02, 2017

                            Lead Product(s) : Autologous Platelet Rich Plasma

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Recipient : University of Wisconsin, Madison

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GENERAL ELECTRIC

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            GENERAL ELECTRIC

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Manganese-Enhanced Mri Contrast Reagent

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : Stanford University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury

                            Details : Manganese-Enhanced Mri Contrast Reagent is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Ischemic Cardiomyopathy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 14, 2016

                            Lead Product(s) : Manganese-Enhanced Mri Contrast Reagent

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Stanford University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            GENERAL ELECTRIC

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            GENERAL ELECTRIC

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Nephrology

                            Study Phase : Phase IV

                            Recipient : VA Greater Los Angeles Healthcare System

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease

                            Details : Acetylcysteine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 19, 2015

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase IV

                            Recipient : VA Greater Los Angeles Healthcare System

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            GENERAL ELECTRIC

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            GENERAL ELECTRIC

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iodixanol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Recipient : Medical University of South Carolina

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aortic Stenosis Pre-Transcatheter Aortic Valve Replacement (TAVR) Procedure CT Scan

                            Details : Iodixanol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Aortic Valve Stenosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 30, 2013

                            Lead Product(s) : Iodixanol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Medical University of South Carolina

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth